Szela Mary T: insider trades.
Szela Mary T reported 5 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 1 open-market purchase ($149K) and 0 sales, across 2 companies.
- Transactions
- 5
- Purchases (P)
- 1
- Sales (S)
- 0
- Companies
- 2
- Name as filed
- Szela Mary T
Companies
| Company | Relationship | Transactions |
|---|---|---|
| TriSalus Life Sciences, Inc. (TLSI) | Director, Officer · CEO and President | 4 |
| Absci Corp | Director | 1 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Absci Corp | P | 12,900 | $11.54 | 21,300 | Form 4 |
| 2026-06-30 | TriSalus Life Sciences, Inc. | A | 3,990 | $3.87 | 1,077,683 | Form 4 |
| 2025-12-31 | TriSalus Life Sciences, Inc. | A | 2,100 | $4.38 | 1,023,826 | Form 5 |
| 2025-06-30 | TriSalus Life Sciences, Inc. | A | 2,848 | $4.23 | 596,726 | Form 5 |
| 2024-12-31 | TriSalus Life Sciences, Inc. | A | 3,530 | $4.26 | 513,207 | Form 5 |
Questions
What stock did Szela Mary T buy or sell?
Szela Mary T reported 5 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 1 open-market purchase ($149K) and 0 sales, across 2 companies.
Is Szela Mary T the same person as other filers with this name?
This page covers SEC CIK 1410289 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/szela-mary-t-1410289.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.